| Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma LH Sehn, AF Herrera, CR Flowers, MK Kamdar, A McMillan, M Hertzberg, ... Journal of Clinical Oncology 38 (2), 155, 2020 | 677 | 2020 |
| Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... The Lancet 395 (10232), 1278-1291, 2020 | 594 | 2020 |
| Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed … M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, ... The Lancet 399 (10343), 2294-2308, 2022 | 374 | 2022 |
| Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma MC Pasquini, ZH Hu, K Curran, T Laetsch, F Locke, R Rouce, ... Blood advances 4 (21), 5414-5424, 2020 | 329 | 2020 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 297 | 2020 |
| PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD BM Haverkos, D Abbott, M Hamadani, P Armand, ME Flowers, ... Blood, The Journal of the American Society of Hematology 130 (2), 221-228, 2017 | 274 | 2017 |
| Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... Leukemia 36 (4), 1171-1175, 2022 | 133 | 2022 |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology WG Wierda, JC Byrd, JS Abramson, SF Bilgrami, G Bociek, D Brander, ... Journal of the National Comprehensive Cancer Network 18 (2), 185-217, 2020 | 124 | 2020 |
| ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic … JP Sharman, V Banerji, LM Fogliatto, Y Herishanu, T Munir, R Walewska, ... Blood 134, 31, 2019 | 106 | 2019 |
| Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by … M Kamdar, SR Solomon, JE Arnason, PB Johnston, B Glass, ... Blood 138, 91, 2021 | 104 | 2021 |
| Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study JS Abramson, SR Solomon, J Arnason, PB Johnston, B Glass, ... Blood 141 (14), 1675-1684, 2023 | 99 | 2023 |
| Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International … S Jaglowski, ZH Hu, Y Zhang, M Kamdar, M Ghosh, P Lulla, J Sasine, ... Blood 134, 766, 2019 | 93 | 2019 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 89 | 2021 |
| Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001 ML Palomba, LI Gordon, T Siddiqi, JS Abramson, M Kamdar, MA Lunning, ... Blood 136, 10-11, 2020 | 78 | 2020 |
| Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. LH Sehn, M Kamdar, AF Herrera, A McMillan, C Flowers, WS Kim, TM Kim, ... Journal of Clinical Oncology 36 (15_suppl), 7507-7507, 2018 | 73 | 2018 |
| PD-1 blockade in mediastinal gray-zone lymphoma C Melani, A Major, J Schowinsky, M Roschewski, S Pittaluga, ES Jaffe, ... New England Journal of Medicine 377 (1), 89-91, 2017 | 68 | 2017 |
| Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ... Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022 | 62 | 2022 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
| Burkitt lymphoma international prognostic index AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, ... Journal of clinical oncology 39 (10), 1129-1138, 2021 | 59 | 2021 |
| NCCN Guidelines® insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 3.2022: featured updates to the NCCN guidelines WG Wierda, J Brown, JS Abramson, F Awan, SF Bilgrami, G Bociek, ... Journal of the National Comprehensive Cancer Network 20 (6), 622-634, 2022 | 52 | 2022 |
